Brean Murray Carret & Co. maintains a 'Buy' on Regeneron Pharma (REGN); Adjusting Eylea Sales Upward

Brean Murray Carret & Co. maintains a 'Buy' on Regeneron Pharma (NASDAQ: REGN), raises price target by $1 to $68.

Brean analyst says, "...As a consequence of these launch numbers, REGN has also given 2012 sales expectations of $140-160 million. We have therefore increased outstanding 2012 sales expectations to $147 million from $107, and the changes to our model increase our target price target to $68. Additionally, REGN reiterated that COGS would remain less than 10% for Eylea in wet-AMD due to the recent lawsuit settlement."

Brean Murray raises FY11 EPS from (2.57) to (2.36) and FY12 from (1.43) to (1.03). Issues FY13 EPS estimate of $0.47.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $65.48 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA approves Regeneron's Pasatru for rare bone disorder FOP
• Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results